• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CoDa boasts positive results in phase IIb study of Nexagon in chronic venous leg ulcers

CoDa boasts positive results in phase IIb study of Nexagon in chronic venous leg ulcers

January 10, 2013
CenterWatch Staff

CoDa Therapeutics, a clinical stage biotechnology company, released positive results from a phase IIb clinical trial of Nexagon in patients with chronic venous leg ulcers, which supports advancing Nexagon into phase III registration trials.

Nexagon is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.

Results showed that Nexagon was safe and showed an increase in complete healing in the randomized, vehicle-controlled, double-blind, phase IIb study. CoDa is preparing a paper describing the results of this trial that will be submitted to a peer-reviewed medical journal.

"CoDa's phase IIb clinical results are very exciting and reflect a well-designed and executed dosing phase study,” said Dr. William Marston, professor and chief of the division of vascular surgery at the University of North Carolina and medical director of the UNC Limb Salvage/Wound Healing Center. “This data will provide clear information to choose an optimal dose and patient profile to move to a pivotal clinical trial. Upon successful completion of this phase, Nexagon would provide a much-needed therapeutic to accelerate healing of chronic venous leg ulcers."

Dr. David Eisenbud, CMO at CoDa and former president of the American Academy of Wound Management, said, "The positive results from the NOVEL2 study substantiate our prior findings from previous VLU studies and suggest that Nexagon could become a game changer: the first prescription medication to enhance the healing of venous leg ulcers. We are designing plans for phase III, and will review the steps to marketing approval at an upcoming end-of-phase II meeting with FDA."

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing